Shanghai Kehua Bio-Engineering Co., Ltd. operates within the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shanghai Kehua Bio-Engineering Co., Ltd. with three other
companies in this sector in China:
MedicalSystem Biotechnology Co Ltd
sales of 3.14 billion Chinese Renmimbi [US$467.29 million]
of which 77%
was In vitro diagnostic reagent),
Beijing Strong Biotechnologies Inc
(774.18 million Chinese Renmimbi [US$115.39 million]
of which 88%
was In vitro detection reagent), and
DA AN Gene Co.,Ltd. Of Sun Yat-Sen University
(1.48 billion Chinese Renmimbi [US$220.39 million]
of which 94%
was Biological Products).
During the year ended December of 2018, sales at
Shanghai Kehua Bio-Engineering Co., Ltd. were 1.99 billion Chinese Renmimbi (US$296.64 million).
increase of 24.8%
versus 2017, when the company's sales were 1.59 billion Chinese Renmimbi.
This was the third consecutive year of growth at Shanghai Kehua Bio-Engineering Co., Ltd..